13F filer · CIK 1512848
NEA Management Company, LLC
TIMONIUM, MD · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$1.6B
$-171.2M vs prior
Positions
26
New / sold out
1 / 1
Added / reduced
0 / 2
Turnover
0.3%
buys $5.6M · sells $410.2M
Top-10 weight
89.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Karyopharm Therapeutics Inc. | +576,780 | – | +$5.6M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Arcellx, Inc. | -3,045,262 | -100.0% | $-349.7M |
| Reduced | Celcuity Inc. | -575,000 | -25.2% | $-60.2M |
| Reduced | CVRx, Inc. | -71,643 | -3.5% | $-368.2K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Trevi Therapeutics, Inc.COM | 13,222,228 | $246.6M | 15.53% |
| 2 | MBX Biosciences, Inc.COM | 3,614,486 | $199.5M | 12.56% |
| 3 | Monte Rosa Therapeutics, Inc.COM | 7,692,298 | $186.2M | 11.72% |
| 4 | Celcuity Inc.COM | 1,710,561 | $179.0M | 11.27% |
| 5 | Spyglass Pharma, Inc.COM SHS | 7,392,301 | $164.6M | 10.36% |
| 6 | Savara, Inc.COM | 24,471,264 | $150.7M | 9.49% |
| 7 | Zenas BioPharma, Inc.COM | 4,023,219 | $102.1M | 6.43% |
| 8 | Coursera, Inc.COM | 12,867,769 | $72.6M | 4.57% |
| 9 | Aurinia Pharmaceuticals, Inc.COM | 3,969,834 | $67.4M | 4.24% |
| 10 | CRISPR Therapeutics AGNAMEN AKT | 1,058,570 | $57.7M | 3.64% |
16 more rows. Subscribe for $29/month to see every row, download the data and use the API.